Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.38, along ...

Avidity Biosciences receives Japan MHLW’s orphan drug status for delpacibart etedesiran to treat myotonic dystrophy type 1: San Diego Thursday, April 10, 2025, 13:00 Hrs [IST] A ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...

Avidity Biosciences, Inc.’s RNA share price has dipped by 7.10%, which has investors questioning if this is right time to buy.

Schroder Investment Management Group boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) by ...

(RTTNews) - Avidity Biosciences, Inc. (RNA), Tuesday said that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation to delpacibart etedesiran for the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Avidity Biosciences (RNA – Research Report), ...

SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...

Avidity Biosciences (RNA) announced the completion of enrollment in the biomarker cohort in the Phase 1/2 Fortitude clinical trial of ...

In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against other unstoppable stocks that could double your money. Generating significant returns ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...